Vesamicol and some of its derivatives: Questionable ligands for selectively labelling acetylcholine transporters in rat brain

European Journal of Pharmacology

Volumn 338, Issue 2, 1997, Pages 177-183

  Custers, Franciscus G J ^a   Leysen, Josée E ^a,b   Stoof, Johannes C ^a   Herscheid, Jacobus D M ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Acetylcholine transporter; AH5183; Alzheimer's disease; SPECT (Single photon emission computed tomography); Vesamicol; binding site

Indexed keywords

1,3 BIS(2 METHYLPHENYL)GUANIDINE; ACETYLCHOLINE; CARRIER PROTEIN; VESAMICOL; VESAMICOL DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN REGION; CHOLINERGIC SYSTEM; CONTROLLED STUDY; FEMALE; GUINEA PIG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPSE VESICLE;

EID: 0030725911     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)81946-2     Document Type: Article

References (15)

1. 3H ]vesamicol binding in brain: autoradiographic distribution, pharmacology, and effects of cholinergic lesions Synapse. 2:1988;486-493.
2. Davis K.L., Powchik P. Tacrine. Lancet. 345:1995;625-630.
3. Tacrine collaborative study group, Davis K.L., Thal L.J., Gamzu E.R., Davis S.C., Woolson R.F., Gracon S.I., Drachman D.A., Schneider L.S., Whitehouse P.J., Hoover T.M., Morris J.C., Kawas C.H., Knopman D.S., Earl N.L., Kumar V., Doody R.S. A double-blind, placebo controlled multicenter trial of tacrine for Alzheimer's disease. New Engl. J. Med. 327:1992;1253-1259.
4. DeLoore K.L., Lesage A.S., Peeters L., Leysen J.E. Various sigma ligands exert long-term protection against glutamate toxicity in primary hippocampal neurones; apparent non involvement of identified sigma-2 sites. Neurosci. Res. Commun. 14:1994;43-51.
5. Efange S.M.N., Mach R.H., Smith C.R., Khare A.B., Foulon C., Akella S.K., Childers S.R., Parsons S.M. Vesamicol analogues as sigma ligands. Biochem. Pharmacol. 49:1995;791-797.
6. Efange S.M.N., Khare A., Parsons S.M., Bau R., Metzenthin T. Nonsymmetrical bipiperidyls as inhibitors of vesicular acetylcholine storage. J. Med. Chem. 36:1993;985-989.
7. 3H ]vesamicol binding in human brain cholinergic deficiency disorders Neurosci. Lett. 117:1990;347-352.
8. Lee H.J., Hammond D.N., Large T.H., Wainer B.H. Immortalized young adult neurones from the septal region: Generation and characterization. Dev. Brain Res. 52:1990;219-228.
9. Marshall I.G., Parsons S.M. The vesicular acetylcholine transport system. Trends Neurol. Sci. 10:1987;174-177.
10. Mohs R.C., Davis B.M., Johns C.A., Mathé A.A., Greenwald B.S., Horvath T.B., Davis K.L. Oral physostigmine treatment of patients with Alzheimer's disease. Am. J. Psychiatr. 142:1985;28-33.
11. Paxinos, G., Watson, C., 1986. The rat brain in stereotaxic coordinates, 2nd ed. Academic Press, Sydney.
12. Perry E.K. The cholinergic hypothesis - ten years on. Br. Med. Bull. 42:1986;63-69.
13. 3H ]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions Neuroscience. 35:1990;327-333.
14. Shiba K., Mori H., Ichikawa A., Tonami N. In vitro characterization of radioiodinated (-)-m-iodovesamicol in rat cerebral membranes. Life Sci. 59:1996;1039-1045.
15. 3H ]tolyl)guanidine: A selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs Proc. Natl. Acad. Sci. USA. 83:1986;8784-8788.